CNAT stock plunged more than 60% Tuesday. Why? The significant drop comes after Conatus Pharmaceuticals (NASDAQ:CNAT) said twenty-four hours prior that it will be implementing a restructuring plan due to its liver disease drug failing in a mid-stage trial.
Here’s everything we know.
CNAT Stock Goes for a Cold PlungeOn Monday, June 24, Conatus Pharmaceuticals said it’ll be exploring new options, as well implementing a restructuring plan after its drug emricasan failed to meet its end goals in a mid-stage trial. In this restructuring plan, Conatus plans to reduce staff by around 40%, ...
Read The Full Article On MicroSmallCap.com
Get early insight on hidden secret gems on MicroSmallCap. Follow Crypto, Mining, Cannabis and Energy stocks and get free research reports here.
All content provided by MicroSmallCap is subject to our Terms Of Use and Disclaimer.